Get the Stockscreener App
9.49
17.48%
-2.01
After Hours:
9.44
-0.05
-0.53%
Capricor Therapeutics Inc stock is traded at $9.49, with a volume of 3.37M.
It is down -17.48% in the last 24 hours and down -38.30% over the past month.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
See More
Previous Close:
$11.50
Open:
$10.48
24h Volume:
3.37M
Relative Volume:
3.09
Market Cap:
$435.75M
Revenue:
$27.10M
Net Income/Loss:
$-24.31M
P/E Ratio:
-11.43
EPS:
-0.83
Net Cash Flow:
$-33.33M
1W Performance:
-28.54%
1M Performance:
-38.30%
6M Performance:
-37.61%
1Y Performance:
+39.76%
1-Day Range:
$9.0101
$10.88
1-Week Range:
$9.0101
$13.81
52-Week Range:
$3.52
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Compare CAPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
9.49 | 435.75M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
New Forecasts: Here's What Analysts Think The Future Holds For Capricor Therapeutics, Inc. (NASDAQ:CAPR) - simplywall.st
Check Out What Whales Are Doing With CAPR - Benzinga
High Growth Tech Stocks In The US Market With Promising Potential - simplywall.st
(CAPR) Trading Signals - Stock Traders Daily
Capricor projects FDA priority review decision for deramiocel by August 2025 - MSN
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2024 Earnings Call Transcript - Insider Monkey
Capricor Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
Capricor Therapeutics Inc (CAPR) Q4 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus
Capricor Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Is Capricor Therapeutics (CAPR) a Worst High-Risk High-Reward Growth Stock to Buy? - Insider Monkey
Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday - Benzinga
Cantor Fitzgerald maintains $30 target on Capricor stock By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains $30 target on Capricor stock - Investing.com
A Glimpse Into The Expert Outlook On Capricor Therapeutics Through 4 Analysts - Benzinga
Capricor Therapeutics Stock (CAPR) Surges on Q4 Results and Promising New Therapy - The Globe and Mail
Capricor Therapeutics Reports 2024 Financial Results - TipRanks
Capricor: Q4 Earnings Snapshot - mySA
Earnings call transcript: Capricor Q4 2024 beats EPS forecast, stock up - Investing.com Canada
Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Capricor Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Capricor Therapeutics Inc Reports Q4 2024 Earnings: EPS Loss of - GuruFocus
Capricor Therapeutics Q4 Loss Widens, Revenue Decreases -March 19, 2025 at 04:39 pm EDT - MarketScreener
Capricor Therapeutics beats Q4 estimates, shares rise on FDA acceptance By Investing.com - Investing.com Canada
Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Capricor's DMD Breakthrough: FDA Fast-Tracks Novel Therapy as Cash Position Hits $151.5M - StockTitan
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely - simplywall.st
While institutions own 38% of Capricor Therapeutics, Inc. (NASDAQ:CAPR), retail investors are its largest shareholders with 49% ownership - Yahoo Finance
Capricor Therapeutics announces long-term data from HOPE-2 OLE study - Yahoo Finance
H.C. Wainwright maintains Capricor stock Buy rating and $77 target By Investing.com - Investing.com UK
Capricor Therapeutics’ (CAPR) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
CAPRICOR THERAPEUTICS Earnings Preview: Recent $CAPR Insider Trading, Hedge Fund Activity, and More - Nasdaq
Capricor Therapeutics Announces Positive Data Demonstrating - GlobeNewswire
Capricor reports promising DMD treatment results - Investing.com
Capricor Therapeutics Says 3-Year Data Show Deramiocel Slows Duchenne Muscular Dystrophy - Marketscreener.com
Capricor reports promising DMD treatment results By Investing.com - Investing.com Australia
Capricor Therapeutics Reports 52% Slowing of Duchenne Muscular Dystrophy Disease Progression with Deramiocel in 3-Year Study Presentation at MDA Conference - Nasdaq
Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy - Yahoo
Breakthrough: New DMD Drug Cuts Disease Progression in Half Over 3 Years - Stock Titan
When the Price of (CAPR) Talks, People Listen - news.stocktradersdaily.com
Capricor touts long-term efficacy of DMD therapy ahead of FDA application - MSN
Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) Price Target at $34.50 - Defense World
Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) PT at $34.50 - Armenian Reporter
Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition - AOL
Capricor at Leerink’s Conference: Strategic Moves in Cell Therapy By Investing.com - Investing.com UK
Rare Disease Biotech Capricor Therapeutics Announces Critical Year-End Earnings Date - StockTitan
Capricor Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 19, 2025 - Nasdaq
Capricor Therapeutics to Present Fourth Quarter and Full - GlobeNewswire
Capricor Therapeutics receives FDA acceptance of BLA for deramiocel - TipRanks
Capricor Therapeutics' Biologics License Application for Deramiocel Accepted by FDA - Marketscreener.com
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):